A mathematical framework for estimating pathogen transmission fitness and inoculum size using data from a competitive mixtures animal model

PLoS Computational Biology

Volumn 7, Issue 4, 2011, Pages

  McCaw, James M ^a,b   Arinaminpathy, Nimalan ^c   Hurt, Aeron C ^d   McVernon, Jodie ^a,b   McLean, Angela R ^e  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PRINCETON UNIVERSITY   (United States)

^d WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ESTIMATION; PATHOGENS; VIRUSES;

ANIMAL MODEL; HUMAN POPULATION; INOCULUM SIZE; MATHEMATICAL FRAMEWORKS; MIXTURE EXPERIMENT; NEURAMINIDASE INHIBITORS; NOVEL STRAINS; SELECTIVE PRESSURE; STRAIN S; UNFOLDINGS;

MIXTURES;

OSELTAMIVIR; SIALIDASE INHIBITOR;

ADVERSE OUTCOME; ALGORITHM; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; COMPETITIVE ABILITY; COMPUTER SIMULATION; CONTROLLED STUDY; EPIDEMIC; HOST PATHOGEN INTERACTION; HOST SUSCEPTIBILITY; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MIXED INFECTION; NONHUMAN; REFERENCE DATABASE; SEASONAL INFLUENZA; STRAIN DIFFERENCE; VIRUS LOAD; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TRANSMISSION; ANTIVIRAL RESISTANCE; BIOLOGICAL MODEL; BIOLOGY; DISEASE TRANSMISSION; GENETICS; HUMAN; INFLUENZA; ORTHOMYXOVIRUS; PATHOGENICITY; PHYSIOLOGY; REPRODUCTIVE FITNESS; VIROLOGY;

ANIMALIA; BACTERIA (MICROORGANISMS); MUSTELA;

ALGORITHMS; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DRUG RESISTANCE, VIRAL; GENETIC FITNESS; HUMANS; INFLUENZA, HUMAN; MODELS, BIOLOGICAL; ORTHOMYXOVIRIDAE;

EID: 79955553616     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1002026     Document Type: Article

References (22)

1. Nicholson KG, Wood JM, Zambon M, (2003) Influenza. Lancet 362: 1733-1745.
2. Blyth CC, Kelso A, McPhie KA, Ratnamohan VM, Catton M, et al. (2010) The impact of the pandemic influenza A(H1N1) 2009 virus on seasonal influenza A viruses in the southern hemisphere, 2009. Euro Surveill 15: pii = 19631.
3. Moss RB, Davey RT, Steigbigel RT, Fang F, (2010) Targeting pandemic influenza: a primer on influenza antivirals and drug resistance. J Antimicrob Chemother 65: 1086-1093.
4. Dharan NJ, Gubareva LV, Meyer JJ, Okomo-Adhiambo M, McClinton RC, et al. (2009) Infections With Oseltamivir-Resistant Influenza A(H1N1) Virus in the United States. JAMA 301: 1034-1041.
5. Hurt AC, Ernest J, Deng YM, Iannello P, Besselaar TG, et al. (2009) Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res 83: 90-93.
6. Meijer A, Lackenby A, Hungnes O, Lina B, van der Werf S, et al. (2009) Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007-08 Season. Emerg Infect Dis 15: 552-560.
7. Herlocher ML, Carr J, Ives J, Elias S, Truscon R, et al. (2002) Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res 54: 99-111.
8. Hurt AC, Nor'e SS, McCaw JM, Fryer HR, Mosse J, et al. (2010) Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model. J Virol 84: 9427-9438.
9. Tang JWT, Lee CK, Lee HK, Loh TP, Chiu L, et al. (2010) Tracking the emergence of pandemic Influenza A/H1N1/2009 and its interaction with seasonal influenza viruses in Singapore. Ann Acad Med Singapore 39: 291-294.
10. Govorkova EA, Ilyushina NA, Marathe BM, McClaren JL, Webster RG, (2010) Competitive fitness of oseltamivir-sensitive and-resistant highly pathogenic H5N1 influenza viruses in a ferret model. J Virol 84: 8042-8050.
11. Duan S, Boltz DA, Seiler P, Li J, Bragstad K, et al. (2010) Oseltamivir-Resistant Pandemic H1N1/2009 Influenza Virus Possesses Lower Transmissibility and Fitness in Ferrets. PLoS Pathog 6: e1001022.
12. McCaw JM, Wood JG, McCaw CT, McVernon J, (2008) Impact of emerging antiviral drug resistance on influenza containment and spread: influence of subclinical infection and strategic use of a stockpile containing one or two drugs. PLoS ONE 3: e2362.
13. Lipsitch M, Cohen T, Murray M, Levin BR, (2007) Antiviral resistance and the control of pandemic influenza. PLoS Med 4: e15.
14. Wu JT, Leung GM, Lipsitch M, Cooper BS, Riley S, (2009) Hedging against Antiviral Resistance during the Next Influenza Pandemic Using Small Stockpiles of an Alternative Chemotherapy. PLoS Medicine 6: e1000085.
15. May RM, Gupta S, McLean AR, (2001) Infectious disease dynamics: What characterizes a successful invader? Philos Trans R Soc Lond B Biol Sci 356: 901-910.
16. Handel A, Longini IM, Antia R, (2010) Towards a quantitative understanding of the within-host dynamics of influenza A infections. J R Soc Interface 7: 35-47.
17. Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS, (2006) Kinetics of influenza A virus infection in humans. J Virol 80: 7590-7599.
18. Hancioglu B, Swigon D, Clermont G, (2007) A dynamical model of human immune response to influenza A virus infection. J Theor Biol 246: 70-86.
19. Handel A, Longini IM, Antia R, (2007) Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread. PLoS Comput Biol 3: e240.
20. Beauchemin C, Samuel J, Tuszynski J, (2005) A simple cellular automaton model for influenza A viral infections. J Theor Biol 232: 223-34.
21. Ferguson NM, Cummings DAT, Cauchemez S, Fraser C, Riley S, et al. (2009) Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 437: 209-214.
22. Abrahams MR, Anderson JA, Giorgi EE, Seoighe C, Mlisana K, et al. (2009) Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol 83: 3556-3567.